Showing 672 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

FDA Approves New Single-Tablet HIV Regimen, Triumeq

Editor's pick
Aidsmeds.com
26 August 2014
The search for a cure

Protein tethers HIV and Ebola to cells

Editor's pick
Futurity
26 August 2014
New & experimental HIV treatments

Theraclone Sciences cuts HIV antibodies deal with Gilead

Editor's pick
San Francisco Business Times (blog)
31 July 2014
New & experimental HIV treatments

The Medicines Patent Pool (MPP) broadens collaboration with Gilead Sciences: Signs licence for Phase III medicine tenofovir alafenamide (TAF)

Editor's pick
Medicines Patent Pool
25 July 2014
Hepatitis C treatment

HIV, HCV and TB Pipeline Report

Editor's pick
Treatment Action Group & i-Base
21 July 2014
New & experimental HIV treatments

Triumeq® (dolutegravir/abacavir/lamivudine) single-tablet regimen receives positive CHMP opinion in Europe for the treatment of HIV

Editor's pick
Viiv Healthcare press release
30 June 2014
Treatment guidelines

Dolutegravir in HIV-1 infection: Added benefit in adult patients

Editor's pick
Science Daily
19 June 2014
New & experimental HIV treatments

Glaxo's ViiV Joins J&J's Janssen to Develop Single-Pill HIV Drug

Editor's pick
Bloomberg
13 June 2014
How HIV works

Paper explores new theory on spread of HIV by "popular" cells

Editor's pick
HIV / AIDS News From Medical News Today
11 June 2014
New & experimental HIV treatments

First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily formulation of raltegravir (Isentress)

Editor's pick
Merck
6 June 2014
New & experimental HIV treatments

Dolutegravir in HIV-1 infection: added benefit in adult patients

Editor's pick
IQWIG
23 May 2014
Pharmaceutical industry

Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA

Editor's pick
Gilead press release
22 April 2014
PrEP

Px Wire: Long-Acting Injectables

Editor's pick
AVAC
17 April 2014
New & experimental HIV treatments

Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

Editor's pick
Bristol-Myers Squibb press release
15 April 2014
The search for a cure

Transplant Drugs May Fight HIV Reservoir

Editor's pick
AIDSMeds
14 April 2014
New & experimental HIV treatments

Nano-sized drug particles to expand HIV treatment further

Editor's pick
Medical Xpress
9 April 2014
Injectable & long-acting HIV treatment

Long-acting HIV drugs advanced to overcome adherence challenge

Editor's pick
Nature Medicine
8 April 2014
Access to healthcare

Viiv Healthcare licenses dolutegravir (Tivicay) to Medicines Patent Pool

Editor's pick
Viiv Healthcare press release
2 April 2014
New & experimental HIV treatments

Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy

Editor's pick
Janssen press release
2 April 2014
Changing treatment

Viral load rebounds in 35% of people using PI/r monotherapy: results of five-year PIVOT study

Editor's pick
HIV i-Base
10 March 2014
The search for a cure

HIV gene therapy using GM cells hailed a success after trial

Editor's pick
The Guardian
5 March 2014
New & experimental HIV treatments

UK: Once-daily HIV pill Tivicay from ViiV gets launch

Editor's pick
Pharma Times
5 February 2014
New & experimental HIV treatments

Researchers open door to new HIV therapy

Editor's pick
University of California Berkeley press release
30 January 2014
Clinical trials

Quality Of Evidence Used By FDA To Approve New Drugs Varies Widely

Editor's pick
Forbes
22 January 2014